Mgb Biopharma
MGB Biopharma was a Scottish biopharmaceutical company founded in 2010 that developed antibiotics based on DNA minor groove binder compounds. Its lead candidate, MGB-BP-3, completed a Phase IIa trial for Clostridioides difficile infection. The company entered liquidation in 2025.
Key facts
| Legal Name | MGB Biopharma Limited |
|---|---|
| UK Company Number | SC362273 |
| Company Operating Status | Closed |
| Full Address | Willow House Kestrel View, Strathclyde Business Park, Bellshill, Scotland, ML4 3PB |
| Incorporation Reference | SC362273 |
| Wellfound ID | mgb-biopharma |